Stock

Madrigal Pharmaceuticals, Inc. MDGL

$542.43-0.17%

All stocks Create account to unlock

Overview

MDGL market data

Price History

MDGL price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for MDGL. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

5 captured

Madrigal Pharmaceuticals Receives Three Resmetirom Patents From U.S. Patent And Trademark Office · Jul 13, 2026, 12:03 PM

8-K filing — MADRIGAL PHARMACEUTICALS, INC. (MDGL) · Jun 17, 2026, 8:06 PM

B of A Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $542 · Jun 11, 2026, 12:10 PM

Madrigal Pharma Announces New Analyses Of Phase 3 Data And Real-World Evidence Demonstrating Rezdiffra Reduced Markers Of Cardiovascular And Liver-Related Risk In Patients With MASH · May 27, 2026, 12:06 PM

Truist Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $709 · May 13, 2026, 3:05 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock